# Raven Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/raven-biotechnologies

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.ravenbio.com
- Total disclosed funding: $40M
- Latest round: Series D (Dec 31, 2007)
- Investors on record: 10

## About

Raven Biotechnologies is engaged in the domain name industry, specializing in the sale and leasing of premium domain names, including its flagship domain RavenBio.com, to foster online presence for businesses and individuals.Founded in 2000 and headquartered in San Francisco, US, Raven Biotechnologies operates as a domain registration and transfer service. The company was acquired by MacroGenics in July 2008 for an undisclosed sum. Raven Biotechnologies has successfully completed 4 deals, with its latest funding round being Series D, raising USD 0.30 mn, bringing the total amount raised to USD 0.30 mn and the current company valuation to USD 81.949 mn.RavenBiotechnologies.com specializes in the sale and leasing of premium domain names, with its core product being the domain RavenBio.com. The company facilitates secure transactions for individuals and businesses seeking to establish an online presence. Their services cater to a global clientele, including entrepreneurs and corporations from North America, Europe, and Asia.Revenue for Raven Biotechnologies is generated through direct sales and leasing agreements for domain names. The flagship domain RavenBio.com is available for a one-time payment of USD 4,995 or via a leasing option priced at USD 714 per month, accommodating various client budgets and preferences.Raven Biotechnologies plans to expand its product offerings and enhance its market presence. The company is exploring upcoming new products related to domain acquisition services and aims to penetrate emerging markets, particularly in Asia and Europe, by the end of 2023. Recent funding will support these initiatives by increasing marketing efforts and expanding operational capabilities.

## Funding rounds

- Series D, Dec 31, 2007, $0.3M — US Venture Partners
- Series C, Jan 3, 2003, $40M — Integra Ventures, US Venture Partners, Presidio Partners, Tekla Capital Management, FirstMark Capital, Horizon Technology Finance Corporation, GE Healthcare, Biomedical Sciences Investment Fund, Bear Stearns Health Innoventures, Milepost Ventures

## Investors

- Integra Ventures (https://capitalatlas.ai/funds/integra-ventures) — Series C
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series C, Series D
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series C
- Horizon Technology Finance Corporation — Series C
- GE Healthcare — Series C
- Biomedical Sciences Investment Fund — Series C
- Bear Stearns Health Innoventures (https://capitalatlas.ai/funds/bear-stearns-health-innoventures) — Series C
- Milepost Ventures (https://capitalatlas.ai/funds/milepost-ventures) — Series C